Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer.

[1]  K. Wallner,et al.  Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. , 2005, Urology.

[2]  A. Kamat,et al.  Atorvastatin: a potential chemopreventive agent in bladder cancer. , 2005, Urology.

[3]  J. Guillem,et al.  Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. , 2005, International journal of radiation oncology, biology, physics.

[4]  L. Seymour,et al.  A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. , 2005, Urologic oncology.

[5]  J. Stamm,et al.  The role of statins in cancer prevention and treatment. , 2005, Oncology.

[6]  S. Sleijfer,et al.  The potential of statins as part of anti-cancer treatment. , 2005, European journal of cancer.

[7]  M. Katz.  Therapy Insight: potential of statins for cancer chemoprevention and therapy , 2005, Nature Clinical Practice Oncology.

[8]  Henk-Jan Guchelaar,et al.  Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. , 2004, Cancer treatment reviews.

[9]  J. Lacal,et al.  Rho GTPases: potential candidates for anticancer therapy. , 2004, Cancer letters.

[10]  M. Kattan,et al.  Statin use is associated with improved biochemical outcome after high-dose radiotherapy for clinically localized prostate cancer , 2003 .

[11]  R. Muschel,et al.  The RAS signal transduction pathway and its role in radiation sensitivity , 2003, Oncogene.

[12]  H. Sandler,et al.  Overview of bladder cancer trials in the Radiation Therapy Oncology Group , 2003, Cancer.

[13]  J. Dunst,et al.  Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Zietman,et al.  Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. , 2002, Urology.

[15]  Y. Matsuzawa,et al.  Hepatocellular Carcinoma (hcc) Causes Death in Patients with Cirrhosis and Is One of the Most Prevalent Malignant Tumours Effect of Pravastatin on Survival in Patients with Advanced Hepatocellular Carcinoma. a Randomized Controlled Trial , 2022 .

[16]  R. Muschel,et al.  Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. , 2000, Cancer research.

[17]  U. Laufs,et al.  Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase* , 1998, The Journal of Biological Chemistry.

[18]  D. Samid,et al.  Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  D. Samid,et al.  Increased radioresistance of ejras‐transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation , 1993, International journal of cancer.

[20]  Z. Darżynkiewicz,et al.  Cell cycle-specific effects of lovastatin. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Sklar.  The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. , 1988, Science.

[22]  A. Einstein,et al.  Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. , 1987, JAMA.

[23]  T. Fitzgerald,et al.  Activated human N‐ras oncogene enhances x‐irradiation repair of mammalian cells in vitro less effectively at low dose rate: Implications for increased therapeutic ratio of low dose rate irradiation , 1985, American journal of clinical oncology.

[24]  Keunchil Park,et al.  Phase II Study of High-Dose Lovastatin in Patients with Advanced Gastric Adenocarcinoma , 2004, Investigational New Drugs.